3 Pharma Stocks You Should be Watching in 2022
Pharma stocks performed relatively poorly in 2021. The SPDR S&P Pharmaceuticals ETF (XPH) was down about (-10.5%), and the SPDR S&P Biotech ETF (XBI) was down about (-20.4%).
The S&P 500 Index was up about 27%, and the NASDAQ was up roughly 21.4% in 2021. This deficit has made pharma stocks a value for investors. In addition, some pharma stocks are yielding over 3%, with conservative payout ratios adding to the attraction.
Three pharma stocks for investors to consider for their portfolios are Merck (NYSE: MRK), Amgen (NASDAQ: AMGN), and Bristol-Myers Squibb (NYSE: BMY). All three stocks are dividend growth stocks with 10+ years of dividend growth.
Merck – A Cash Cow
Merck's R&D strengths and the recent acquisition of Acceleron are restocking the pipeline, especially in oncology. This fact portends well for Merck’s shareholders.
Merck’s forward dividend yield of ~3.4% is supported by a solid free cash flow of approximately $8,158 million in the last 12-months. Earnings per share cover the dividend, and the payout ratio is conservative at about 47%.
Amgen – High Dividend Growth
The company has a portfolio of solid therapies, including Neulasta (neutropenia), Enbrel (autoimmune diseases), Prolia (osteoporosis), Xgeva (fracture in cancer patients), Kyprolis (multiple myeloma), Repatha (cholesterol), and Aimovig (migraines).
SWIPE UP TO READ MORE!
Discover more from wealthofgeeks.com